Minocycline inhibits antigen processing for presentation to human T cells: Additive inhibition with chloroquine at therapeutic concentrations

Clinical Immunology

Volumn 113, Issue 3, 2004, Pages 270-277

  Kalish, Richard S ^a   Koujak, Susan ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Anti inflammatory; Antigen processing; Chloroquine; Minocycline; T lymphocytes; Tetracycline

Indexed keywords

CHLOROQUINE; DOXYCYCLINE; MINOCYCLINE; PARAFORMALDEHYDE; TETANUS TOXOID; TETRACYCLINE;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CELL PROLIFERATION; CELLS, CULTURED; CHLOROQUINE; DOXYCYCLINE; HUMANS; MINOCYCLINE; T-LYMPHOCYTES; TETANUS TOXOID;

EID: 7044270687     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.07.012     Document Type: Article

References (45)

1. J.R. O'Dell, C.E. Haire, W. Palmer, W. Drymalski, S. Wees, K. Blakely, M. Churchill, P.J. Eckhoff, A. Weaver, D. Doud, N. Erikson, F. Dietz, R. Olson, P. Maloley, L.W. Klassen, and G.F. Moore Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial Arthritis Rheum. 40 1997 842 848
2. M. Kloppenburg, B.A. Dijkmans, C.L. Verweij, and F.C. Breedveld Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline Immunopharmacology 31 1996 163 169
3. B.C. Tilley, G.S. Alarcon, S.P. Heyse, D.E. Trentham, R. Neuner, D.A. Kaplan, D.O. Clegg, J.C. Leisen, L. Buckley, and S.M. Cooper Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial, MIRA Trial Group Ann. Intern. Med. 122 1995 81 89
4. M. Stone, P.R. Fortin, C. Pacheco-Tena, and R.D. Inman Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity J. Rheumatol. 30 2003 2112 2122
5. A.G. Butterfield, D.W. Hughes, N.J. Pound, and W.L. Wilson Separation and detection of tetracyclines by high-speed liquid chromatography Antimicrob. Agents Chemother. 4 1973 11 15
6. W.C. Barringer, W. Schultz, G.M. Sieger, and R.A. Nash Minocycline hydrochloride and its relationship to other tetracyclines Am. J. Pharm. 146 1974 179 191
7. +-ATPase in murine macrophages J. Biol. Chem. 265 1990 21099 21107
8. V. Ferrari, and D.J. Cutler Temperature dependence of the acid dissociation constants of chloroquine J. Pharm. Sci. 76 1987 554 556
9. H.K. Ziegler, and E.R. Unanue Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells Proc. Natl. Acad. Sci. U. S. A. 79 1982 175 178
10. R.S. Kalish, C. Morimoto, and S.F. Schlossman Characterization of the T4 helper inducer subset for the generation of cytotoxicity to alloantigen Cell. Immunol. 111 1998 379
11. R.S. Kalish, J.A. Wood, and A. LaPorte Processing of urushiol (poison ivy) hapten by both endogenous and exogenous pathways for presentation to human T-cells J. Clin. Invest. 93 1994 2039 2047
12. A. Bauer, I. Rutenfranz, and H. Kirchner Processing requirements for T cell activation by Mycoplasma arthridis-derived mitogen Eur. J. Immunol. 18 1988 2109 2112
13. K. Bhardwaj, and M.J. Colston The processing and presentation of mycobacterial antigens by human monocytes Eur. J. Immunol. 18 1988 691 696
14. R.J. Shimonkevitz, J. Kappler, P. Marrack, and H. Grey Antigen recognition by H-2 restricted T cells I, Cell-free antigen processing J. Exp. Med. 158 1983 303 316
15. E.A. Kurt-Jones, D.I. Beller, S.B. Mizel, and E.R. Unanue Identification of a membrane-associated interleukin 1 in macrophages Proc. Natl. Acad. Sci. U. S. A. 82 1985 1204 1208
16. R.N. Germain The ins and outs of antigen processing and presentation Nature (Lond.) 322 1986 687 689
17. M.T. Sweetser, L.A. Morrison, V.L. Braciale, and T.J. Baciale Recognition of pre-processed endogenous antigen by class I but not class II MHC-restricted T cells Nature (Lond.) 342 1989 180 182
18. J.G. Nuchtern, J.S. Bonifacino, W.E. Biddison, and R.D. Klausner Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation Nature (Lond) 339 1989 223 225
19. S. Ohkuma, and B. Poole Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents Proc. Natl. Acad. Sci. U. S. A. 75 1978 3327 3331
20. H. Kropshofer, A.B. Vogt, and G.J. Hammerling Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding Proc. Natl. Acad. Sci. U. S. A. 92 1995 8313 8317
21. D.J. Wallace Antimalarial agents and lupus Rheum. Dis. Clin. North Am. 20 1994 243 263
22. I.M. Meinao, E.I. Sato, L.E. Andrade, M.B. Ferraz, and E. Atra Controlled trial with chloroquine diphosphate in systemic lupus erythematosus Lupus 5 1996 237 241
23. M.M. Khraishi, and G. Singh The role of anti-malarials in rheumatoid arthritisâ€"the American experience Lupus 5 Suppl 1 1996 S41 S44
24. L.M. Golub, N.S. Ramamurthy, T.F. McNamara, R.A. Greenwald, and B.R. Rifkin Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs Crit. Rev. Oral. Biol. Med. 2 1991 297 321
25. Y. Liu, N. Ramamurthy, J. Marecek, H.M. Lee, J.L. Chen, M.E. Ryan, B.R. Rifkin, and L.M. Golub The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs) Curr. Med. Chem. 8 2001 243 252
26. V. Brundula, N.B. Rewcastle, L.M. Metz, C.C. Bernard, and V.W. Yong Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis Brain 125 2002 1297 1308
27. K.H. Reeta, P.K. Mediratta, P. Mahajan, and K.K. Sharma Effect of minocycline and tetracycline on immunological responses in experimental animals Indian J. Med. Sci. 56 2002 553 559
28. G. Opdenakker, E. Van den Steen, and J. Van Damme Gelatinase B: a tuner and amplifier of immune functions Trends Immunol. 22 2001 571 579
29. I. Nelissen, E. Martens, P.E. Van den Steen, P. Proost, I. Ronsse, and G. Opdenakker Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy Brain 126 2003 1371 1381
30. T. Sadowski, and J. Steinmeyer Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes J. Rheumatol. 28 2001 336 340
31. J.M. Clements, J.A. Cossins, G.M. Wells, D.J. Corkill, K. Helfrich, L.M. Wood, R. Pigott, G. Stabler, G.A. Ward, A.J. Gearing, and K.M. Miller Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor J. Neuroimmunol. 74 1997 85 94
32. K. Gijbels, S. Masure, H. Carton, and G. Opdenakker Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders J. Neuroimmunol. 41 1992 29 34
33. P. Proost, J. Van Damme, and G. Opdenakker Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein Biochem. Biophys. Res. Commun. 192 1993 1175 1181
34. N. Popovic, A. Schubart, B.D. Goetz, S.C. Zhang, C. Linington, and I.D. Duncan Inhibition of autoimmune encephalomyelitis by a tetracycline Ann. Neurol. 51 2002 215 223
35. S.E. Tett Clinical pharmacokinetics of slow-acting antirheumatic drugs Clin. Pharmacokinet. 25 1993 392 407
36. PDR 58 Edition, 2004, Thomson PDR, Montvale, NY, pp. 1901.
37. M.A. Sande, and G.L. Mandell Chapter 48 Antimicrobal agents A.G. Gilman T.W. Rall A.S. Nies P. Taylor Goodman and Gilman's The Pharmacologic Basis of Therapeutics eight ed. 1990 Pergamon Press New York 1117 1119
38. F.C. Anett HLA and the spondyloarthropathies A. Calin Spondyloarthropathies 1984 Grune and Stratton New York 297 322
39. T. Lehner, K.I. Welsh, and J.R. Batchelor The relationship of HLA-B and DR phenotypes to Behcet's syndrome, recurrent oral ulceration and the class of immune complexes Immunology 47 1982 581 587
40. G. Thomson HLA disease associations: models for the study of complex human genetic disorders Crit. Rev. Clin. Lab. Sci. 32 1995 183 219
41. T. Hohler, A. Weinmann, P.M. Schneider, C. Rittner, R.E. Schopf, J. Knop, P. Hasenclever, K.H. Meyer zum Buschenfelde, and E. Marker-Hermann TAP-polymorphisms in juvenile onset psoriasis and psoriatic arthritis Hum. Immunol. 51 1996 49 54
42. R. Wolf, and V. Ruocco Triggered psoriasis Adv. Exp. Med. Biol. 455 1999 221 225
43. A. Gilhar, M. David, Y. Ullmann, T. Berkutski, and R.S. Kalish T-Lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice J. Invest. Dermatol. 109 1997 283 288
44. V. Brazzelli, M. Quaglini, M. Martinetti, G. Nolli, L. Salvaneschi, M. Cuccia, and G. Borroni A peculiar sequence motif in the alpha-1-domain of the HLA-C molecule in psoriasis Dermatology 200 2000 99 103
45. J. Bhalerao, and A.M. Bowcock The genetics of psoriasis: a complex disorder of the skin and immune system Hum. Mol. Genet. 7 1998 1537 1545